Menu Search
Equities

Oxford Biodynamics PLC

OBD:LSE

Oxford Biodynamics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.35
  • Today's Change0.173 / 14.62%
  • Shares traded8.29m
  • 1 Year change-96.05%
  • Beta1.8890
Data delayed at least 20 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Oxford Biodynamics PLC had net income fall 61.34% from a loss of 6.71m to a larger loss of 10.83m despite a 231.17% increase in revenues from 154.00k to 510.00k. An increase in the cost of goods sold as a percentage of sales from 24.68% to 47.84% was a component in the falling net income despite rising revenues.
Gross margin41.49%
Net profit margin-1,800.32%
Operating margin-1,848.30%
Return on assets-87.64%
Return on equity-266.70%
Return on investment-114.28%
More ▼

Cash flow in GBPView more

In 2023, Oxford Biodynamics PLC increased its cash reserves by 439.01%, or 4.28m. Cash Flow from Financing totalled 13.21m or 2,589.61% of revenues. In addition the company used 8.29m for operations while cash used for investing totalled 620.00k.
Cash flow per share-0.0538
Price/Cash flow per share--
Book value per share0.008
Tangible book value per share-0.0022
More ▼

Balance sheet in GBPView more

Oxford Biodynamics PLC has a Debt to Total Capital ratio of 78.73%, a higher figure than the previous year's 74.82%.
Current ratio0.6758
Quick ratio0.6156
Total debt/total equity3.70
Total debt/total capital0.7873
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.